Jan 23, 2025 · For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube. About …

Jan 23, 2025 · Under terms of the agreement, Neomorph will receive an upfront payment from AbbVie, and is eligible to receive up to $1.64 billion in aggregate option fees and milestones, …

Jan 23, 2025 · Collaboration leverages AbbVie’s expertise in oncology and immunology drug development and Neomorph’s leading molecular glue discovery platform; Neomorph to receive …

6 days ago · AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across …

Jan 23, 2025 · Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue …

6 days ago · Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion in milestone payments. AbbVie and Neomorph have …

Jan 23, 2025 · Under terms of the agreement, Neomorph will receive an upfront payment from AbbVie, and is eligible to receive up to $1.64 billion in aggregate option fees and milestones, …

6 days ago · AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and immunology, with the deal worth $1.64bn. …

Jan 23, 2025 · In a licensing deal that could reach up to $1.64 billion, AbbVie is teaming up with Neomorph to develop molecular glue degraders, a modality that has caught Big Pharma’s …

6 days ago · AbbVie and Neomorph, Inc. have partnered to develop molecular glue degraders targeting oncology and immunology. These small molecules selectively degrade proteins …